bio2018-mybio-sessionicon-companypres

Landos Biopharma Company Presentation

3:15 PM–3:30 PM Jun 5, 2019

Theater 1

Description

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing, initiated Phase 2 clinical testing of BT-11 for ulcerative colitis and plans a Phase 2 trial in Crohn’s disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which will advance to IND in 2019.

Session ID: 551945

Tags